Here are the 10-K annual reports from Yubo Intl Biotech Ltd A (YBGJ) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow YBGJ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full YBGJ filings page.
Yubo International Biotech Limited is a New York holding company whose China operations run through a Cayman and Hong Kong structure and contractual arrangements with a Chinese variable interest entity, Yubo Beijing. Investors in Class A shares hold no direct equity in the PRC operating companies.
Yubo Beijing focuses on endometrial stem cell technologies, aiming to build what it describes as the first public endometrial stem cell bank and selling “VIVCELL” branded light application products for respiratory health, skincare, hair care, beverages, and personal care in China. The VIE structure and related contracts have not been tested in court and could be invalidated or restricted by PRC authorities.
The company highlights extensive risks from evolving Chinese regulation on foreign investment, data security, cybersecurity review, overseas offerings, and potential HFCAA-related trading prohibitions. It reports a history of losses and expresses substantial doubt about its ability to continue as a going concern, while revenue in 2025 came from a single customer buying light application products.